Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Waldenstrom Macroglobulinemia 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Fallopian Tube Neoplasms 1Chondrosarcoma, Mesenchymal 1Chondrosarcoma, Clear Cell 1Chondrosarcoma 1Breast Neoplasms 1Anemia 1Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

Paclitaxel 17Carboplatin 16Magnetic Resonance Spectroscopy 11Taxes 10Specimen Handling 10Bevacizumab 10olaparib 9Gemcitabine 9pembrolizumab 8Immunoglobulin G 7Disulfides 7Biopsy 7liposomal doxorubicin 6Doxorubicin 5cediranib 4Nivolumab 4Cyclophosphamide 4Cisplatin 4oregovomab 3niraparib 3adavosertib 3X-Rays 3Topotecan 3tremelimumab 2rucaparib 2mirvetuximab soravtansine 2berzosertib 2aldesleukin 2Surveys and Questionnaires 2Platinum 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Fallopian Tube Neoplasms × Pharmacogenomic Testing × Clear all
NCT01012817 2026-04-29

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
88 enrolled 23 charts
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡